Last year Zhang, Kuriyan and colleagues demonstrated that an asymmetric dimer interaction between EGF receptor kinase domains is a key element of receptor activation. They now show that a cellular protein that inhibits receptor activity targets this dimer interface, not only uncovering an important regulatory mechanism but also opening a new route to therapeutic kinase inhibition.
